Clinical trial · Interventional
Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections
A Multicenter, Randomized, Double-masked Phase 3a Study to Assess Safety and Efficacy of Brolucizumab 6 mg q4 Weeks Compared to Aflibercept 2 mg q4 Weeks in Patients With Neovascular Age-related Macular Degeneration (nAMD) With Persistent Retinal Fluid (MERLIN)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Sponsor Decision
Summary
Brief summary (as posted)
This clinical study was designed to compare the safety and efficacy of brolucizumab 6 mg dosed every 4 weeks to aflibercept 2 mg dosed every 4 weeks in those neovascular age-related macular degeneration (nAMD) patients with retinal fluid despite frequent anti-Vascular Endothelial Growth Factor (VEGF) injections.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Age-Related Macular Degeneration | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Aflibercept | Biological | Aflibercept | ALIAS |
| Brolucizumab | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Brolucizumab
- description
- Brolucizumab 6 mg dosed every 4 weeks was administered via intravitreal injection for 100 weeks.
- interventionNames
- Biological: Brolucizumab
- type
- ACTIVE_COMPARATOR
- label
- Aflibercept
- description
- Aflibercept 2 mg dosed every 4 weeks was administered via intravitreal injection for 100 weeks.
- interventionNames
- Biological: Aflibercept
Primary outcomes (1)
- measure
- Change From Baseline in Best-Corrected Visual Acuity (BCVA) at Week 52
- timeFrame
- Baseline, week 52
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 50 Years
Show eligibility criteria text
Inclusion Criteria: * Signed informed consent * Diagnosis of wet age-related macular degeneration (AMD) * Currently receiving anti-VEGF injections Exclusion Criteria: * Active infection or inflammation in either eye * Significant fibrosis in the study eye * Recent ocular surgery * Uncontrolled glaucoma * Use of medications as specified in the protocol * Pregnant, nursing * Of child-bearing potential unless using highly effective method of contraception
References
Publications (0)
Data not yet available